(Q39674995)

English

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

scientific article published on July 27, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients (English)

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664024

11 June 2024

author name string

Jeff Sperinde

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Xueguang Jin

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Jayee Banerjee

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Elicia Penuel

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Anasuya Saha

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Gundo Diedrich

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Weidong Huang

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kim Leitzel

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Jodi Weidler

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Eva-Maria Fuchs

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Michael Bates

14

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Gordon Parry

15

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

John Winslow

16

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Allan Lipton

17

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Suhail M. Ali

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664024

11 June 2024

Christian F. Singer

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664024

11 June 2024

Wolfgang J. Köstler

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664024

11 June 2024

language of work or name

0 references

publication date

27 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

https://aacrjournals.org/clincancerres/article-pdf/16/16/4226/1990574/4226.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664024

11 June 2024

http://clincancerres.aacrjournals.org/cgi/content/abstract/16/16/4226

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664024

11 June 2024

https://aacrjournals.org/clincancerres/article-pdf/16/16/4226/1990574/4226.pdf

Portable Document Format

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

4226-4235

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Untangling the ErbB signalling network

1

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

2

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

3

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

4

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer

5

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

6

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

7

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

8

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology

9

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer

10

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

11

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

12

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Purification of Her-2 extracellular domain and identification of its cleavage site

13

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

14

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

15

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

16

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

17

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.

18

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

B7-h4 is highly expressed in ductal and lobular breast cancer

19

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.

24

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

25

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells

26

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells

27

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans

28

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx

29

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

30

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance

31

1 reference

10.1158/1078-0432.CCR-10-0410

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0410

11 June 2024

Identifiers

10.1158/1078-0432.CCR-10-0410

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39674995&oldid=2178999871"